CLAIMS

1. Use of type I polymerized collagen in the manufacture of a medicament for the treatment of cytokine storm, inflammation and pulmonary fibrosis in patients infected by the SARS-CoV2 virus (Covid -19) with mild to moderate disease, wherein the medicament is adapted to be administered every 12 h for 3 days, after 3 days, every 24 h for 4 days.

2. Use of type I polymerized collagen in the manufacture of a medicament for the treatment of cytokine storm, inflammation and pulmonary fibrosis in patients infected by the SARS-CoV2 virus (Covid-19) with severe to semi-critical illness, wherein the medicament is adapted to be administered every 12 h for 7 days.

3. The use according to claims 1 and 2, wherein the medicament is formulated to be administered intramuscularly.

4. The use according to claim 1, wherein the medicament is formulated to be administered intramuscularly in a dose

of 1.5 ml of the active ingredient for 3 days every 12 hours and for 4 days every 24 hours for a total of 7 days of treatment with a total dose of 15 ml of Collagen-PVP in patients with Covid-19 pneumonia.

5. The use according to claim 2, wherein the medicament is formulated to be administered intramuscularly in a dose of 1.5 ml of the active ingredient for 7 days every 12 with a total dose of 21 ml of Collagen-PVP in patients with Covid-19 pneumonia.

6. The use according to claims 1 and 2, to generate changes in the levels of systemic inflammation and soluble pro-inflammatory mediators, as well as fibrosis that can be determined at 7- and 14-days post-treatment.

7. The use according to claims 1 and 2, wherein each positive COVID-19 patient was evaluated at the time of diagnosis for desaturation, headache and alterations in respiratory rate, fever, alterations in heart rate, cough, dyspnea, odynophagia, alterations in the sense of taste, arthralgia and myalgia, anosmia and chest pain to

determine clinical improvement.

8. The use according to claims 1 and 2, wherein in advanced stages of COVID-19 disease desaturation, headache and alterations in respiratory rate, fever, alterations in heart rate, cough, dyspnea, odynophagia, alterations in the sense of taste, arthralgia and myalgia, anosmia and chest pain were evaluated to determine clinical improvement.

9. The use according to claims 1 and 2, wherein the medicament is formulated to produce no side- or adverse effects.